{"id":20945,"date":"2025-01-08T15:45:27","date_gmt":"2025-01-08T07:45:27","guid":{"rendered":"https:\/\/flcube.com\/?p=20945"},"modified":"2025-01-08T15:45:28","modified_gmt":"2025-01-08T07:45:28","slug":"abbvie-exercises-option-for-capsidas-neurodegenerative-disease-program","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20945","title":{"rendered":"AbbVie Exercises Option for Capsida’s Neurodegenerative Disease Program"},"content":{"rendered":"\n

US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV<\/a>) has exercised its option for the first neurodegenerative disease program as part of their collaboration formed in 2023. As a result, Capsida will receive a USD 40 million license payment and is eligible for additional milestones and royalties.<\/p>\n\n\n\n

Results and Decision Basis<\/strong>
The decision was based on promising results from primate studies, which demonstrated that Capsida’s engineered adeno-associated virus (AAV) capsids can effectively deliver AbbVie’s novel therapeutic cargo intravenously (IV). This capability highlights the potential of Capsida’s technology to advance treatments for neurodegenerative diseases.<\/p>\n\n\n\n

Roles and Responsibilities<\/strong>
AbbVie will be responsible for advancing the program into IND-enabling studies and conducting clinical trials, while Capsida will take charge of manufacturing. This division of responsibilities leverages the strengths of both companies to accelerate the development of innovative therapies for neurodegenerative diseases.<\/p>\n\n\n\n

Significance of the Collaboration<\/strong>
This milestone underscores the ongoing collaboration between Capsida Biotherapeutics and AbbVie, highlighting their shared commitment to advancing cutting-edge treatments for neurodegenerative conditions. The partnership is poised to drive significant progress in the development of therapies that could improve patient outcomes in this critical area.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV) has exercised its option…<\/p>\n","protected":false},"author":1,"featured_media":20947,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[234,3082,853],"class_list":["post-20945","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-abbvie","tag-capsida-biotherapeutics","tag-nyse-abbv"],"yoast_head":"\nAbbVie Exercises Option for Capsida's Neurodegenerative Disease Program - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV) has exercised its option for the first neurodegenerative disease program as part of their collaboration formed in 2023. As a result, Capsida will receive a USD 40 million license payment and is eligible for additional milestones and royalties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20945\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Exercises Option for Capsida's Neurodegenerative Disease Program\" \/>\n<meta property=\"og:description\" content=\"US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV) has exercised its option for the first neurodegenerative disease program as part of their collaboration formed in 2023. As a result, Capsida will receive a USD 40 million license payment and is eligible for additional milestones and royalties.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20945\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T07:45:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-08T07:45:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0808.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"616\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20945#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20945\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie Exercises Option for Capsida’s Neurodegenerative Disease Program\",\"datePublished\":\"2025-01-08T07:45:27+00:00\",\"dateModified\":\"2025-01-08T07:45:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20945\"},\"wordCount\":202,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20945#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0808.png\",\"keywords\":[\"AbbVie\",\"Capsida Biotherapeutics\",\"NYSE: ABBV\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20945#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20945\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20945\",\"name\":\"AbbVie Exercises Option for Capsida's Neurodegenerative Disease Program - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20945#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20945#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0808.png\",\"datePublished\":\"2025-01-08T07:45:27+00:00\",\"dateModified\":\"2025-01-08T07:45:28+00:00\",\"description\":\"US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV) has exercised its option for the first neurodegenerative disease program as part of their collaboration formed in 2023. As a result, Capsida will receive a USD 40 million license payment and is eligible for additional milestones and royalties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20945#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20945\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20945#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0808.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0808.png\",\"width\":1080,\"height\":616,\"caption\":\"AbbVie Exercises Option for Capsida's Neurodegenerative Disease Program\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20945#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Exercises Option for Capsida’s Neurodegenerative Disease Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie Exercises Option for Capsida's Neurodegenerative Disease Program - Insight, China's Pharmaceutical Industry","description":"US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV) has exercised its option for the first neurodegenerative disease program as part of their collaboration formed in 2023. As a result, Capsida will receive a USD 40 million license payment and is eligible for additional milestones and royalties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20945","og_locale":"en_US","og_type":"article","og_title":"AbbVie Exercises Option for Capsida's Neurodegenerative Disease Program","og_description":"US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV) has exercised its option for the first neurodegenerative disease program as part of their collaboration formed in 2023. As a result, Capsida will receive a USD 40 million license payment and is eligible for additional milestones and royalties.","og_url":"https:\/\/flcube.com\/?p=20945","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-08T07:45:27+00:00","article_modified_time":"2025-01-08T07:45:28+00:00","og_image":[{"width":1080,"height":616,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0808.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20945#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20945"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie Exercises Option for Capsida’s Neurodegenerative Disease Program","datePublished":"2025-01-08T07:45:27+00:00","dateModified":"2025-01-08T07:45:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20945"},"wordCount":202,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=20945#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0808.png","keywords":["AbbVie","Capsida Biotherapeutics","NYSE: ABBV"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20945#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20945","url":"https:\/\/flcube.com\/?p=20945","name":"AbbVie Exercises Option for Capsida's Neurodegenerative Disease Program - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=20945#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=20945#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0808.png","datePublished":"2025-01-08T07:45:27+00:00","dateModified":"2025-01-08T07:45:28+00:00","description":"US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV) has exercised its option for the first neurodegenerative disease program as part of their collaboration formed in 2023. As a result, Capsida will receive a USD 40 million license payment and is eligible for additional milestones and royalties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20945#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20945"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=20945#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0808.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0808.png","width":1080,"height":616,"caption":"AbbVie Exercises Option for Capsida's Neurodegenerative Disease Program"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20945#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie Exercises Option for Capsida’s Neurodegenerative Disease Program"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0808.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20945","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20945"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20945\/revisions"}],"predecessor-version":[{"id":20948,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20945\/revisions\/20948"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/20947"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20945"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20945"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}